Merck to offer 100 million settlement in NuvaRing lawsuits

Merck to offer $100 million settlement in NuvaRing lawsuits
Merck will pay $100 million to settle thousands of lawsuits over the company's NuvaRing birth control device, according to insiders.

(HealthDay)—Merck will pay $100 million to settle thousands of lawsuits over the company's NuvaRing birth control device, according to insiders.

The will be announced Friday and provide an average payout of more than $58,000 per case, two people familiar with the told Bloomberg News. They did not want to be identified because they hadn't been authorized to talk publicly about the accord.

The deal will resolve several thousand cases in federal and state courts in Missouri and New Jersey. Women accused Merck of selling NuvaRing even though the company knew that the device put them at higher risk for than products from other companies.

A Merck spokeswoman declined to comment on the settlement, Bloomberg reported.

More information: Other Health Highlights: Feb. 7, 2014

add to favorites email to friend print save as pdf

Related Stories

Germany's Merck to buy materials supplier AZ

Dec 05, 2013

Germany's Merck KGaA has announced plans to buy AZ Electronic Materials, which supplies high-tech materials for the electronics industry, for about 1.6 billion pounds ($2.6 billion).

Belgium's Ablynx in Merck cancer research tie-up: firm

Feb 03, 2014

Belgian biotechnology company Ablynx said on Monday it has signed a cancer research cooperation accord with US pharmaceuticals giant Merck & Co. which could be worth up to 1.7 billion euros ($2.3 billion).

Merck's Vioxx cases drag on

Aug 21, 2007

Lawsuits related to the painkiller Vioxx have little prospect of resolution for the thousands who have sued the drug company Merck, it was reported.

Merck: FDA wants more studies of insomnia drug

Jul 01, 2013

Drugmaker Merck & Co. says federal regulators have ruled that they won't approve high doses of its experimental insomnia medication because of concerns about their safety.

Recommended for you

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments